Education
About Us
Working with TipRanks
Follow Us
FYC - ETF AI Analysis
Top Page
First Trust Small Cap Growth AlphaDEX Fund (FYC)
Rating:62Neutral
Price Target:
$92.00
Positive Factors
Strong Top Holdings
Several of the ETF’s top holdings, such as GRAIL Inc and Navitas Semiconductor, have delivered strong year-to-date performance, boosting overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Health Care, Industrials, and Technology, reducing reliance on any single industry.
Healthy Year-to-Date Performance
The fund has shown solid year-to-date performance, indicating strong momentum in its holdings.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which can eat into investor returns over time.
Overwhelming U.S. Exposure
With nearly all assets concentrated in U.S. companies, the fund lacks geographic diversification and is vulnerable to domestic market risks.
Small Cap Volatility
The focus on small-cap stocks increases the potential for higher volatility and risk during market downturns.
FYC vs. SPDR S&P 500 ETF (SPY)
AUM615.85M
RegionNorth America
Expense Ratio0.70%
Beta1.13
IssuerFirst Trust
Inception DateApr 19, 2011
Dividend Yield0.24%
Asset ClassEquity
Index TrackedNASDAQ AlphaDEX Small Cap Growth Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume56,809
30 Day Avg. Volume45,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
115.50Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering263
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FYC Summary
The First Trust Small Cap Growth AlphaDEX Fund (FYC) is an ETF that focuses on small-cap companies in the U.S. with strong growth potential. It follows the NASDAQ AlphaDEX Small Cap Growth Index, which uses a unique strategy to select stocks based on growth factors. Some of its holdings include companies like Praxis Precision Medicines and Microvast Holdings. Investors might consider FYC for its potential to deliver high growth and diversify their portfolio with smaller, dynamic companies. However, it’s important to note that small-cap stocks can be more volatile, meaning their prices may rise and fall more dramatically than larger, established companies.
How much will it cost me?The expense ratio for the First Trust Small Cap Growth AlphaDEX Fund (FYC) is 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund uses an actively managed strategy to select stocks based on growth factors, rather than passively tracking an index.
What would affect this ETF?The First Trust Small Cap Growth AlphaDEX Fund (FYC) could benefit from strong economic growth in the U.S., which often supports small-cap companies, as well as advancements in sectors like health care, technology, and industrials where the ETF has significant exposure. However, rising interest rates or economic slowdowns could negatively impact small-cap growth stocks, as these companies often rely on borrowing to fund expansion and are more sensitive to market volatility. Regulatory changes in key sectors like health care or technology could also pose risks to the fund’s performance.
FYC Top 10 Holdings
The First Trust Small Cap Growth AlphaDEX Fund (FYC) leans heavily into health care, industrials, and technology, with health care alone making up over a quarter of its portfolio. Stocks like Cidara Therapeutics and GRAIL Inc are rising stars, benefiting from strong technical momentum and promising pipelines, driving much of the fund’s performance. However, names like Praxis Precision Medicines are lagging, weighed down by weak financials despite some optimism around future developments. With its U.S.-focused small-cap growth strategy, the fund is a high-risk, high-reward play for investors seeking dynamic opportunities in niche sectors.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines | 1.35% | $8.86M | $4.77B | 155.56% | 54 Neutral | |
| Cidara Therapeutics | 1.17% | $7.69M | $6.92B | 1078.44% | 57 Neutral | |
| Arcutis Biotherapeutics | 1.04% | $6.82M | $3.77B | 185.61% | 60 Neutral | |
| GRAIL Inc | 0.96% | $6.30M | $4.34B | 530.09% | 70 Outperform | |
| Avadel Pharmaceuticals | 0.95% | $6.27M | $2.24B | 104.28% | 57 Neutral | |
| Travere Therapeutics | 0.95% | $6.26M | $3.20B | 96.86% | 55 Neutral | |
| Alphatec Holdings | 0.90% | $5.93M | $3.06B | 114.45% | 58 Neutral | |
| NewAmsterdam Pharma Company | 0.88% | $5.78M | $4.46B | 86.74% | 58 Neutral | |
| Argan | 0.87% | $5.76M | $5.14B | 136.88% | 75 Outperform | |
| Adaptive Biotechnologies | 0.87% | $5.72M | $3.12B | 266.67% | 53 Neutral |
FYC Technical Analysis
Positive
―
Price Trends
92.25
Negative
87.67
Positive
80.07
Positive
Market Momentum
-0.81
Positive
51.39
Neutral
35.25
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FYC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 92.26, equal to the 50-day MA of 92.25, and equal to the 200-day MA of 80.07, indicating a neutral trend. The MACD of -0.81 indicates Positive momentum. The RSI at 51.39 is Neutral, neither overbought nor oversold. The STOCH value of 35.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FYC.
FYC Peer Comparison
Comparison Results
Performance Comparison
FYC
First Trust Small Cap Growth AlphaDEX Fund
92.18
8.30
9.90%
OUSM
OShares U.S. Small-Cap Quality Dividend ETF
―
―
―
FYX
First Trust Small Cap Core AlphaDEX Fund
―
―
―
VIOG
Vanguard S&P Small-Cap 600 Growth ETF
―
―
―
ISCG
iShares Morningstar Small-Cap Growth ETF
―
―
―
JSML
Janus Henderson Small Cap Growth Alpha ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents